By Vin Gurrieri ( April 21, 2015, 8:28 PM EDT) -- Bristol-Myers Squibb Co. has urged the U.S. Supreme Court to reject an opposition by Teva Pharmaceuticals USA Inc. and review a Federal Circuit's decision to invalidate a patent on hepatitis B drug Baraclude, saying the panel's decision is wrong and conflicts with high court precedent....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.